Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3WCL4)

Drug Name

Baltaleucel-T Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Phase 2	[1]
Hodgkin lymphoma	2B30	Phase 2	[1]
Lymphoma	2A80-2A86	Phase 2	[1]
Post-transplant lymphoproliferative disorder	2B32	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting T-cells (T-cells)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATG-Fresenius S	DM4VJ5Q	Transplant rejection	NE84	Phase 3	[2]
DiabeCell	DMK6FYR	Insulin-dependent diabetes	5A10	Phase 2	[3]
TVI-Kidney-1	DMGYSZ0	Renal cell carcinoma	2C90	Phase 2	[4]
T2c-001	DM06GDC	Congestive heart failure	BD10	Phase 2	[3]
BPX-501	DMIMA4V	Acute lymphoblastic leukaemia	2A85	Phase 1/2	[1]
AX-024	DMRQ32K	Multiple sclerosis	8A40	Phase 1	[5]
RTL-1000	DM1B4CQ	Multiple sclerosis	8A40	Phase 1	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of Neovii Biotech.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	Clinical pipeline report, company report or official report of TVAX Biomedical.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	RTL THERAPY FOR MULTIPLE SCLEROSIS: A Phase I Clinical Study. J Neuroimmunol. 2011 February; 231(1-2): 7-14.